All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2025-03-03.
From the record
ADMA Biologics Inc's filings since 2017 show 3 warning events of 2 kinds: an auditor change (8-K item 4.01, 2 times, the latest 2024-10-31); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2025-03-03) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+64.6% a year over 6 filed years; profitable in 2 of 6.
From the record
ADMA Biologics Inc's 6 filed years say what it did: revenue went from $42 million in fiscal 2020 to $510 million in fiscal 2025, up 64.6% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 2 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 7.4% a year. 18% of cash flow returned. Insiders: 11 sales, 5 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, ADMA Biologics Inc's diluted share count grew about 7.4% a year, and dividends and buybacks returned about 18% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 11 sales (10 under scheduled 10b5-1 plans) and 5 purchases of their own stock on the open market in the year to 2026-11-05, buying about $468 thousand (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 31%: 31¢ of profit per shareholder dollar. Leverage 24%: owes 24¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, ADMA Biologics Inc earned about 31 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 47 cents per dollar of everything the company owns. Leverage: it owed about 24 cents per dollar of assets, and net share issuance: its share count grew 0.6% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 15% of 102 in its family; net margin 28.8%.
From the record
ADMA Biologics Inc's standing among 102 graded names in its industry family: revenue of $510 million in fiscal 2025 ranks in the top 13% by size; a net margin of 28.8% ranks in the top 10%; revenue growth of 49% a year over the last 3 filed years ranks in the top 20% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 50% of 110 in its family for leadership; chief executive since 2012.
From the record
ADMA Biologics Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Grossman, Adam S (President and CEO, as filed), filing under that title since 2012-02-15, 14.7 years (top 2% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 4.1 years (bottom 22%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 31%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 32% of 92 in its family for room to expand.
From the record
ADMA Biologics Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $88 million against debt of $72 million leaves 2.5% of its assets as net cash, bottom 9% of its family; cash from operations less capital spending is 5.5% of revenue (top 18%); a gross margin of 57.4% (bottom 37%); research spending of 0.9% of revenue (bottom 2%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 41% of 100 in its family for growth drivers.
From the record
ADMA Biologics Inc's growth drivers, from the filed years to fiscal 2025: revenue grew 49% a year over the last three filed years against 64.6% over all 6, slowing (bottom 35% of its family); the newest year grew 19.6% (top 47%); research spending grew 9.6% a year (top 34%); capital spending grew 17.5% a year (top 19%) (its annual reports). ADMA Biologics Inc reported 2 lines of business in fiscal 2025: ADMA Bio Manufacturing at $493 million (97%), Plasma Collection Centers at $17 million (3%); 2 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 43% of 72 in its family for expectations against reality.
From the record
ADMA Biologics Inc's newest year against its own record: revenue of $510 million in fiscal 2025 came in 28.1% below the $709 million its prior three years' pace pointed to (bottom 23% of its family); net income of $147 million against a prior three-year average of $35 million (top 3%); a net margin of 28.8% against -2.5% before (top 49%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made